allscripts also paid $ 1.7 million of cash consideration to us as an estimated working capital payment , and we recorded a receivable of $ 1.0 million related to final working capital adjustments . we are also responsible for paying allscripts for fulfilling certain customer service obligations of the business post-closing . - 80 - concurrent with the closing and as contemplated by the apa , we and allscripts modified the amended and restated mutual license and reseller agreement dated june 26 , 2015 , which was further amended on december 30 , 2017 , such that , among other things , the company committed to deliver a minimum of $ 95.0 million of total bookings over a ten-year period ( “ bookings commitment ” ) from referral transactions and sales of certain allscripts products under this agreement ( see note 3 of the consolidated and combined financial statements ) . in the event of a bookings commitment shortfall at the end of the ten-year period , we may be obligated to pay 70 % of the shortfall , subject to certain credits . we will earn 30 % commission from allscripts on each software referral transaction that results in a booking with allscripts . we account for the bookings commitment at its estimated fair value over the life of the agreement and , as of december 31 , 2017 , the estimated fair value was not material . the sale of the business qualified as a discontinued operations because it comprised operations and cash flows that could be distinguished , operationally and for financial reporting purposes , from the rest of the company . the disposal of the business sold to allscripts represented a strategic shift in the company 's operations as the sale enables the company to focus on genomic sequencing , clinical decision support , connected care and payer engagement . the consummation of the transactions contemplated by the apa is reflected in the consolidated and combined financial statements . 2017 corporate restructuring plan in august 2017 , we committed to and began implementation of a comprehensive restructuring plan that includes a wide range of organizational efficiency initiatives and other cost reduction opportunities . the plan will allow us to focus on our core competencies of genomic sequencing , clinical decision support , connected care and payer engagement . we incurred charges from this restructuring related to severance and other cash expenditures and recognized the majority of the expenses related to this restructuring in the year ended december 31 , 2017 . 2016 developments and acquisition on june 7 , 2016 , we completed our ipo , whereby we sold 6,500,000 shares of our common stock at a public offering price of $ 14.00 per share . additionally , on june 9 , 2016 , the underwriters partially exercised their overallotment option to purchase an additional 400,000 shares of our common stock at $ 14.00 per share . we received a total of $ 83.6 million in net proceeds from our ipo , after deducting underwriting discounts and commissions and offering costs of $ 13.0 million . the offering was registered under the securities act of 1933 , as amended , on a registration statement on form s-1 ( registration no . 333-211196 ) , as amended . in december 2016 , we issued convertible notes to a related party and others for net proceeds of $ 9.9 million and $ 92.8 million , respectively , after deducting underwriting discounts and commissions and other offering costs of $ 4.3 million . please see note 12 of the notes to consolidated and combined financial statements for further discussion of these convertible notes . non-gaap net loss from continuing operations and non-gaap net loss per share from continuing operations adjusted net loss from continuing operations and adjusted net loss per share from continuing operations are financial measures that are not prepared in conformity with united states generally accepted accounting principles ( u.s. gaap ) . our management believes that the presentation of non-gaap financial measures provides useful supplementary information regarding operational performance , because it enhances an investor 's overall understanding of the financial results for our core business . additionally , it provides a basis for the comparison of the financial results for our core business between current , past and future periods . other companies may define these measures in different ways . non-gaap financial measures should be considered only as a supplement to , and not as a substitute for or as a superior measure to , financial measures prepared in accordance with u.s. gaap . non-gaap net loss from continuing operations excludes the effects of ( 1 ) corporate restructuring expenses from continuing operations , ( 2 ) acquisition related compensation expense , ( 3 ) acquisition-related sales incentives , which have been recorded as contra revenue , ( 4 ) intangible amortization from continuing operations , ( 5 ) loss from equity method investments , ( 6 ) non-cash interest expense related to convertible notes , ( 7 ) change in fair value of derivatives liability , ( 8 ) stock-based compensation expense from continuing operations , ( 9 ) bp settlement other income , ( 10 ) securities litigation costs , and ( 11 ) benefit from ( provision for ) income taxes adjustment includes the impact of the conversion from a limited liability corporation to a corporation , the impact of convertible notes offering and the impact of intangibles amortization , and the impact of the `` tax act `` of 2017 . story_separator_special_tag million compared to the prior year . this growth was primarily driven by higher revenue from our navinet and eviti solutions . maintenance revenue increased $ 1.3 million , or 14.7 % , from $ 9.1 million in the year ended december 31 , 2016 to $ 10.4 million for the year ended december 31 , 2017 . this increase was primarily driven by an increase in deviceconx post contract support maintenance from a larger number of licenses under maintenance . sequencing and molecular analysis revenue increased from $ 0.6 million for the year ended december 31 , 2016 to $ 2.6 million for the year ended december 31 , 2017. this increase was primarily due to a larger number of gps samples sequenced and recognized as revenue as compared with last year as a result of either receiving reimbursement from non-contracted payers or from deliveries to patients covered by a contract payer of the gps test . currently , we recognize revenue from clients with executed contracts , from signed single case agreements , and from clients without a contractual agreement where we recognize revenue on a cash basis given the uncertainty over reimbursement . as the company gains additional insurance coverage and reimbursement experience , we expect to be able to reduce the portion of gps revenue which is recognized on a cash basis . we have significantly expanded our sales efforts by adding seasoned sales and account management professionals in 2017. in 2017 , we grew our gps provider-facing sales team from 5 to 13 professionals , including an international sales professional in the second quarter of 2017. with the growth of the sales team , we expect to continue to gain traction with physicians in new areas of the us and have seen continued year over year growth in the number of physicians ordering our test . - 90 - the commercial team 's efforts are focused on increasing reimbursement of the gps cancer profile by developing partnerships , which include pilot arrangements with commercial insurance and self-insured employers , expanding physician relationships , and enhancing operational performance and efficiencies . the partnership strategy that we developed for commercial health plans supports an alignment with designated provider/oncology groups within the health plan 's network . we work directly with the physician groups to support education of test ordering and interpretation and enable aggregate review of results with the plans . in the initial pilot arrangement that we have with commercial health plan , reimbursement is recognized for each test order throughout the pilot arrangement and the gps cancer profile value is assessed by the plan with the goal of full medical policy adoption at pilot end . we have grown the number of payers and self-insured employers covering our gps cancer test and have added several national self- insured employers . we will continue to invest resources in this area and expect growth as a result of our efforts . our pipeline includes several national and regional health plans and we expect to announce additional pilot contracts before year end . the self-insured employer pipeline includes opportunities with many companies listed on fortune 's 100 list . finally , we are pursuing international opportunities via partnerships with locally based resellers around the world . during the third quarter of 2017 , we entered into a reseller agreement for gps cancer with a large singapore-based reseller . under this agreement , the reseller will distribute gps cancer to physicians in singapore , malaysia , thailand , vietnam , and the philippines . this new contract expands gps cancer beyond our existing international coverage in israel , italy , mexico , and the middle east . we have also continued focused efforts to enhance reimbursement from plans when profiles are ordered and there is no payer contract in place . we are actively engaging plans with detail which supports a physician 's reason for ordering . our utilization of pre-authorizations and supporting documentation assists in the overall billing and appeal process ; optimizing payment with payers , who do not have a formal agreement with us . the gps cancer profile provides all information that can be found in other market molecular tests that physicians deem necessary for treatment recommendation and expands insight for the oncologist with the comprehensive information available on each patient tested . other services revenue decreased $ 0.9 million , or 11.0 % , from $ 7.8 million in 2016 to $ 6.9 million for the year ended december 31 , 2017 . this was primarily driven by a $ 0.6 million decrease in non-pcs device con x revenue due to the timing of project implementations , a $ 0.2 million decrease in non-pcs navinet open revenue as well as a $ 0.1 million decrease in home health services . we believe that significant opportunities exist for expanded cross-sell opportunities of our suite of solutions across our existing customer base , including eviti and navinet customer bases . we also believe that our customer base and our product solutions provide unique opportunities to expand the volume of gps sequencing analysis reporting to our customer base . maintaining our current customer base will be important to our future maintenance and saas recurring revenue streams . comparison of the years ended december 31 , 2015 and 2016 total revenue increased $ 34.2 million , or 74.1 % , from the year ended december 31 , 2015 to $ 80.4 million for the year ended december 31 , 2016. our total revenue growth was driven primarily by our acquisition of navinet in january 2016. our acquisition of navinet resulted in the contribution of $ 40.9 million mainly in saas revenue in the year ended december 31 , 2016. total software-related revenue was $ 63.0 million for the year ended december 31 , 2016 compared to $ 28.2 million for the year ended december 31 , 2015 , an increase of $ 34.7 million or 123.1 % .

cash used in operating activities of $ 81.1 million in the year ended december 31 , 2017 was a result of our continued significant investments in research and development , sales and marketing , and increased expenses incurred as we became a public company , including costs associated with public company reporting and corporate governance requirements , and other expenses incurred to grow our business . in the year ended december 31 , 2017 , $ 102.7 million , or 59 % of our net loss of $ 175.2 million consisted of non-cash items , including a $ 4.5 million in stock-based compensation , $ 28.1 million of depreciation and amortization , a $ 50.3 million equity in net loss of a related party investment , $ 9.6 million of loss on sale of business and dissolution of business component , $ 5.1 million deferred income taxes , net expense , a $ 0.2 million provision for accounts receivable bad debts , a $ 0.7 million inventory provision , $ 4.4 million amortization of debt discounts and deferred financing offering costs , and partially offset by a $ 0.3 million decrease in fair value of derivatives liability . cash used in operating activities in the year ended december 31 , 2017 included a decrease in prepaid expenses and other current assets of $ 0.6 million , a $ 2.2 million increase in deferred implementation costs due to an increase in business activity associated with the growth of our business , $ 1.9 million in reduction in accounts payable , $ 6.3 million reduction in accrued and other liabilities , a $ 1.0 million decrease in deferred revenue , and a $ 0.3 million increase in other assets and liabilities .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash used in operating activities of $ 81.1 million in the year ended december 31 , 2017 was a result of our continued significant investments in research and development , sales and marketing , and increased expenses incurred as we became a public company , including costs associated with public company reporting and corporate governance requirements , and other expenses incurred to grow our business . in the year ended december 31 , 2017 , $ 102.7 million , or 59 % of our net loss of $ 175.2 million consisted of non-cash items , including a $ 4.5 million in stock-based compensation , $ 28.1 million of depreciation and amortization , a $ 50.3 million equity in net loss of a related party investment , $ 9.6 million of loss on sale of business and dissolution of business component , $ 5.1 million deferred income taxes , net expense , a $ 0.2 million provision for accounts receivable bad debts , a $ 0.7 million inventory provision , $ 4.4 million amortization of debt discounts and deferred financing offering costs , and partially offset by a $ 0.3 million decrease in fair value of derivatives liability . cash used in operating activities in the year ended december 31 , 2017 included a decrease in prepaid expenses and other current assets of $ 0.6 million , a $ 2.2 million increase in deferred implementation costs due to an increase in business activity associated with the growth of our business , $ 1.9 million in reduction in accounts payable , $ 6.3 million reduction in accrued and other liabilities , a $ 1.0 million decrease in deferred revenue , and a $ 0.3 million increase in other assets and liabilities .
```    
 Suspicious Activity Report : allscripts also paid $ 1.7 million of cash consideration to us as an estimated working capital payment , and we recorded a receivable of $ 1.0 million related to final working capital adjustments . we are also responsible for paying allscripts for fulfilling certain customer service obligations of the business post-closing . - 80 - concurrent with the closing and as contemplated by the apa , we and allscripts modified the amended and restated mutual license and reseller agreement dated june 26 , 2015 , which was further amended on december 30 , 2017 , such that , among other things , the company committed to deliver a minimum of $ 95.0 million of total bookings over a ten-year period ( “ bookings commitment ” ) from referral transactions and sales of certain allscripts products under this agreement ( see note 3 of the consolidated and combined financial statements ) . in the event of a bookings commitment shortfall at the end of the ten-year period , we may be obligated to pay 70 % of the shortfall , subject to certain credits . we will earn 30 % commission from allscripts on each software referral transaction that results in a booking with allscripts . we account for the bookings commitment at its estimated fair value over the life of the agreement and , as of december 31 , 2017 , the estimated fair value was not material . the sale of the business qualified as a discontinued operations because it comprised operations and cash flows that could be distinguished , operationally and for financial reporting purposes , from the rest of the company . the disposal of the business sold to allscripts represented a strategic shift in the company 's operations as the sale enables the company to focus on genomic sequencing , clinical decision support , connected care and payer engagement . the consummation of the transactions contemplated by the apa is reflected in the consolidated and combined financial statements . 2017 corporate restructuring plan in august 2017 , we committed to and began implementation of a comprehensive restructuring plan that includes a wide range of organizational efficiency initiatives and other cost reduction opportunities . the plan will allow us to focus on our core competencies of genomic sequencing , clinical decision support , connected care and payer engagement . we incurred charges from this restructuring related to severance and other cash expenditures and recognized the majority of the expenses related to this restructuring in the year ended december 31 , 2017 . 2016 developments and acquisition on june 7 , 2016 , we completed our ipo , whereby we sold 6,500,000 shares of our common stock at a public offering price of $ 14.00 per share . additionally , on june 9 , 2016 , the underwriters partially exercised their overallotment option to purchase an additional 400,000 shares of our common stock at $ 14.00 per share . we received a total of $ 83.6 million in net proceeds from our ipo , after deducting underwriting discounts and commissions and offering costs of $ 13.0 million . the offering was registered under the securities act of 1933 , as amended , on a registration statement on form s-1 ( registration no . 333-211196 ) , as amended . in december 2016 , we issued convertible notes to a related party and others for net proceeds of $ 9.9 million and $ 92.8 million , respectively , after deducting underwriting discounts and commissions and other offering costs of $ 4.3 million . please see note 12 of the notes to consolidated and combined financial statements for further discussion of these convertible notes . non-gaap net loss from continuing operations and non-gaap net loss per share from continuing operations adjusted net loss from continuing operations and adjusted net loss per share from continuing operations are financial measures that are not prepared in conformity with united states generally accepted accounting principles ( u.s. gaap ) . our management believes that the presentation of non-gaap financial measures provides useful supplementary information regarding operational performance , because it enhances an investor 's overall understanding of the financial results for our core business . additionally , it provides a basis for the comparison of the financial results for our core business between current , past and future periods . other companies may define these measures in different ways . non-gaap financial measures should be considered only as a supplement to , and not as a substitute for or as a superior measure to , financial measures prepared in accordance with u.s. gaap . non-gaap net loss from continuing operations excludes the effects of ( 1 ) corporate restructuring expenses from continuing operations , ( 2 ) acquisition related compensation expense , ( 3 ) acquisition-related sales incentives , which have been recorded as contra revenue , ( 4 ) intangible amortization from continuing operations , ( 5 ) loss from equity method investments , ( 6 ) non-cash interest expense related to convertible notes , ( 7 ) change in fair value of derivatives liability , ( 8 ) stock-based compensation expense from continuing operations , ( 9 ) bp settlement other income , ( 10 ) securities litigation costs , and ( 11 ) benefit from ( provision for ) income taxes adjustment includes the impact of the conversion from a limited liability corporation to a corporation , the impact of convertible notes offering and the impact of intangibles amortization , and the impact of the `` tax act `` of 2017 . story_separator_special_tag million compared to the prior year . this growth was primarily driven by higher revenue from our navinet and eviti solutions . maintenance revenue increased $ 1.3 million , or 14.7 % , from $ 9.1 million in the year ended december 31 , 2016 to $ 10.4 million for the year ended december 31 , 2017 . this increase was primarily driven by an increase in deviceconx post contract support maintenance from a larger number of licenses under maintenance . sequencing and molecular analysis revenue increased from $ 0.6 million for the year ended december 31 , 2016 to $ 2.6 million for the year ended december 31 , 2017. this increase was primarily due to a larger number of gps samples sequenced and recognized as revenue as compared with last year as a result of either receiving reimbursement from non-contracted payers or from deliveries to patients covered by a contract payer of the gps test . currently , we recognize revenue from clients with executed contracts , from signed single case agreements , and from clients without a contractual agreement where we recognize revenue on a cash basis given the uncertainty over reimbursement . as the company gains additional insurance coverage and reimbursement experience , we expect to be able to reduce the portion of gps revenue which is recognized on a cash basis . we have significantly expanded our sales efforts by adding seasoned sales and account management professionals in 2017. in 2017 , we grew our gps provider-facing sales team from 5 to 13 professionals , including an international sales professional in the second quarter of 2017. with the growth of the sales team , we expect to continue to gain traction with physicians in new areas of the us and have seen continued year over year growth in the number of physicians ordering our test . - 90 - the commercial team 's efforts are focused on increasing reimbursement of the gps cancer profile by developing partnerships , which include pilot arrangements with commercial insurance and self-insured employers , expanding physician relationships , and enhancing operational performance and efficiencies . the partnership strategy that we developed for commercial health plans supports an alignment with designated provider/oncology groups within the health plan 's network . we work directly with the physician groups to support education of test ordering and interpretation and enable aggregate review of results with the plans . in the initial pilot arrangement that we have with commercial health plan , reimbursement is recognized for each test order throughout the pilot arrangement and the gps cancer profile value is assessed by the plan with the goal of full medical policy adoption at pilot end . we have grown the number of payers and self-insured employers covering our gps cancer test and have added several national self- insured employers . we will continue to invest resources in this area and expect growth as a result of our efforts . our pipeline includes several national and regional health plans and we expect to announce additional pilot contracts before year end . the self-insured employer pipeline includes opportunities with many companies listed on fortune 's 100 list . finally , we are pursuing international opportunities via partnerships with locally based resellers around the world . during the third quarter of 2017 , we entered into a reseller agreement for gps cancer with a large singapore-based reseller . under this agreement , the reseller will distribute gps cancer to physicians in singapore , malaysia , thailand , vietnam , and the philippines . this new contract expands gps cancer beyond our existing international coverage in israel , italy , mexico , and the middle east . we have also continued focused efforts to enhance reimbursement from plans when profiles are ordered and there is no payer contract in place . we are actively engaging plans with detail which supports a physician 's reason for ordering . our utilization of pre-authorizations and supporting documentation assists in the overall billing and appeal process ; optimizing payment with payers , who do not have a formal agreement with us . the gps cancer profile provides all information that can be found in other market molecular tests that physicians deem necessary for treatment recommendation and expands insight for the oncologist with the comprehensive information available on each patient tested . other services revenue decreased $ 0.9 million , or 11.0 % , from $ 7.8 million in 2016 to $ 6.9 million for the year ended december 31 , 2017 . this was primarily driven by a $ 0.6 million decrease in non-pcs device con x revenue due to the timing of project implementations , a $ 0.2 million decrease in non-pcs navinet open revenue as well as a $ 0.1 million decrease in home health services . we believe that significant opportunities exist for expanded cross-sell opportunities of our suite of solutions across our existing customer base , including eviti and navinet customer bases . we also believe that our customer base and our product solutions provide unique opportunities to expand the volume of gps sequencing analysis reporting to our customer base . maintaining our current customer base will be important to our future maintenance and saas recurring revenue streams . comparison of the years ended december 31 , 2015 and 2016 total revenue increased $ 34.2 million , or 74.1 % , from the year ended december 31 , 2015 to $ 80.4 million for the year ended december 31 , 2016. our total revenue growth was driven primarily by our acquisition of navinet in january 2016. our acquisition of navinet resulted in the contribution of $ 40.9 million mainly in saas revenue in the year ended december 31 , 2016. total software-related revenue was $ 63.0 million for the year ended december 31 , 2016 compared to $ 28.2 million for the year ended december 31 , 2015 , an increase of $ 34.7 million or 123.1 % .

